225 related articles for article (PubMed ID: 18650450)
21. [Expression and clinical significance of IKZF1 gene IK6 isoform in adult acute lymphoblastic leukemia].
Yuan T; Zhao XL; Zhang LX; Li QH; Tian Z; Tang KJ; Wang Y; Lin D; Li W; Liu BC; Zhou CL; Wang M; Wang JX; Mi YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):539-43. PubMed ID: 23815894
[TBL] [Abstract][Full Text] [Related]
22. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Santos FP; Cortes J
Expert Opin Pharmacother; 2012 Nov; 13(16):2381-95. PubMed ID: 22992064
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
Reddiconto G; Chiusolo P; Fiorini A; Farina G; Sorà F; Leone G; Sica S
Leuk Lymphoma; 2007 Oct; 48(10):2054-7. PubMed ID: 17917973
[No Abstract] [Full Text] [Related]
26. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Thomas X; Dombret H
Leuk Lymphoma; 2008 Jul; 49(7):1246-54. PubMed ID: 18452076
[TBL] [Abstract][Full Text] [Related]
27. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Ikaros family splicing variants in human hematopoietic lineages.
Matulić M; Paradzik M; Puskarić BJ; Stipić J; Antica M
Coll Antropol; 2010 Mar; 34(1):59-62. PubMed ID: 20432734
[TBL] [Abstract][Full Text] [Related]
29. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.
Thomas DA
Hematology Am Soc Hematol Educ Program; 2007; ():435-43. PubMed ID: 18024662
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
31. Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.
Lin X; Zou X; Wang Z; Fang Q; Chen S; Huang J; Zhe N; Yu M; Zhang Y; Wang J
Oncotarget; 2016 Aug; 7(33):53679-53701. PubMed ID: 27447561
[TBL] [Abstract][Full Text] [Related]
32. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zuo Z; Jones D; Yao H; Thomas DA; O'Brien S; Ravandi F; Kantarjian HM; Abruzzo LV; Medeiros LJ; Chen SS; Luthra R
Mod Pathol; 2010 Nov; 23(11):1524-34. PubMed ID: 20729815
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
34. Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.
Dong Y; Liu F; Wu C; Li S; Zhao X; Zhang P; Jiao J; Yu X; Ji Y; Zhang M
Clin Exp Immunol; 2016 Sep; 185(3):320-31. PubMed ID: 27198500
[TBL] [Abstract][Full Text] [Related]
35. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
Vitanza NA; Zaky W; Blum R; Meyer JA; Wang J; Bhatla T; Morrison DJ; Raetz EA; Carroll WL
Pediatr Blood Cancer; 2014 Oct; 61(10):1779-85. PubMed ID: 24976218
[TBL] [Abstract][Full Text] [Related]
36. High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.
Tokunaga K; Yamaguchi S; Iwanaga E; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2013 Sep; 91(3):201-208. PubMed ID: 23751147
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
Tachibana T; Numata A; Tanaka M; Motohashi K; Fujisawa S; Fujita H; Sakai R; Tomita N; Maruta A; Ishigatsubo Y; Kanamori H
Leuk Lymphoma; 2011 Jul; 52(7):1376-9. PubMed ID: 21438838
[No Abstract] [Full Text] [Related]
38. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
39. Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.
Hato T; Yamanouchi J; Tamura T; Hojo N; Niiya Y; Kohno M; Bando S; Yakushijin Y; Takada K; Sakai I; Yasukawa M; Fujita S
Int J Hematol; 2004 Jul; 80(1):62-6. PubMed ID: 15293570
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.
Jing Y; Chen H; Liu M; Zhou M; Guo Y; Gao C; Wang Q; Li H; Zhao Y; Bo J; Huang W; Zhu H; Zhang Y; Yu L
PLoS One; 2014; 9(11):e110431. PubMed ID: 25415187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
